CClinicalTrials.gg
CompletedNCT03556540Updated Aug 13, 2020

Influence of Exercise in Patients With Chronic Kidney Disease During Hemodialysis

An interventional study of physical exercise in Chronic Kidney Diseases, sponsored by Universidade Metodista de Piracicaba. Completed at 1 site in Brazil. Open to participants aged 40 Years to 70 Years. Per ClinicalTrials.gov, last updated 2020-08-13.

Sponsored by Universidade Metodista de Piracicaba · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
40 Years to 70 Years
Sex
All
01

Study summary

Introduction: Chronic Renal Failure affects a large part of the world population, being characterized by irreversible renal tissue damage, resulting in systemic disturbances that negatively affect the patient's life. The most commonly used treatment is hemodialysis, which also has certain deleterious effects, so it is necessary to look for therapies that minimize these complications. Objective: To analyze the influence of physical exercise during hemodialysis on the autonomic heart rate modulation, quality of life and physical functional ability in individuals with Chronic Renal Failure at Hospital das Clínicas Gaspar Vianna. Method: The intervention consists on performing aerobic exercise during hemodialysis. For the evaluation will be applied the KDQOL-SF ™ 1.3 questionnaire, for quality of life; 6-Minute Walk Test for physical functional ability; and cardiofrequencimeter for the autonomic heart rate modulation. Data will be stored in Microsoft Excel® spreadsheets, it will also be used for making graphs and tables. Statistical analysis will be performed in the Bioestat 5.3® program and the choice of tests will depend on the distribution and homogeneity of the data.

Read the detailed description

This is a randomized, prospective and quantitative clinical trial, whose patients will be selected after analysis of the inclusion and exclusion criteria, which will be performed in the Hemodialysis sector of the State Public Foundation Gaspar Vianna Clinical Hospital.

The target population of this study will consist of individuals with chronic renal failure undergoing hemodialysis. The volunteers of the study will be randomly randomized by a blind researcher who does not know the protocol, groups or volunteers that will be inserted in the study, being allocated in Control Group and Experimental Group.

The sample calculation was performed using the GraphPad StatMate application, version 1.01, with a significance of 5% and a test power of 80%, being used as reference the number of cases found in the literature, being determined that 20 volunteers will be included in the study With chronic kidney disease and who undergo hemodialysis treatment.

In the study, individuals who attend the Monteiro Leite Hemodialysis Center, aged 40 to 70 years, undergoing hemodialysis, only in the FPEHCGV, 3 times a week with a minimum of 6 months of hemodialysis.

Will be excluded from the research, individuals who are hospitalized at the Gaspar Vianna Clinic Hospital or that during the application of the protocol are hospitalized, have osteomioarticular diseases that prevent the proposed exercise, patients who use drugs that influence the heart rhythm , Patients with values of less than 24 points in the evaluation of the mini state of mental assessment, patients with a pacemaker installed, patients who underwent previous cardiac surgery less than six months, patients with a body mass index greater than 30 / kg / m2 .

For the data collection will be used: Polarimeter of the brand POLAR®, model RS800CX (Polar Electro TM, Kempele, Finland); Premium® Aneroid Sphygmomanometer and Premium® Brand Stethoscope, Rappaport Model (Wenzhou Instruments Co; China); Nonin Pulse Oximeter, KDQOL - SF ™ 1.3 Scale and Modified Borg Scale (CR10). Samples will be collected in the control and experimental groups before the start of the protocol, 1 month after protocol initiation, at the end of the protocol and 1 month after the end of the protocol.

For the evaluation of the autonomic modulation of the HR will be used the analysis of the variability of the same, at the moment of the evaluation, after one month of intervention, in the second month and at the end of the collection. The collections will be performed between 8:00 a.m. to 12:00 p.m. and 3:00 p.m. to 7:00 p.m., in order to minimize influences of the circadian cycle on the variability of the HR.

During the evaluation, respiratory rate and blood pressure will be monitored in order to discard their influence on heart rate variability.

At collection, the patients will be positioned first in prone and then supine and finally in standing position. For each analysis, they will be kept in rest for 10 minutes - at each position - allowing the stabilization of vital signs. Next, the HR and the iR-R will be recorded, with a duration of 10 minutes, and the patient will be advised not to perform movements and not to talk during the collection period.

The recording of HRV will be performed by means of a POLAR® brand, RS800CX (Polar Electro ™, Kempele, Finland) cardiofrequency meter, where the HR signal will be captured by a tape with the signal receiver, placed in the thorax of the Patient at the time of the xiphoid process of the sternum.

The transfer of the data recorded by the frequencymeter will be evaluated for the Polar ProTrainer Software (Polar Electro OY, Kempele, Finland) through an infrared signal emitting interface, where it will be stored and subsequently exported in .txt format so that later , Is analyzed in the program Kubios HRV 2.2 (MATLAB, Kuopio, Finland) and saved in the computer with the collection time.

For the analysis, there will be a selection of a five-minute stretch containing the highest signal stability, discarding the initial 30 seconds and the final 30 seconds of collection, provided that it comprises at least 5 minutes or 256 points.

The analysis of the variables in the time domain will be: square root of the square mean of the differences between adjacent normal RR intervals (rMSSD), standard deviation of all normal RR intervals recorded in a time interval (SDNN), and variables in the domain of the Frequency: low frequency spectral component (BF), high frequency spectral component (AF), BF / AF ratio and nonlinear variables: Poincaré plot width (SD1), and Shannon entropy.

It will be evaluated by the 6-Minute Walk Test. It is performed from the placement of 2 cones, one at each end of a 30-meter course. The maximum distance covered by the patient is evaluated in 6 minutes, with walking rhythm respecting its limits, and can not run.

Heart and respiratory rate, blood pressure, shortness of breath, fatigue in the legs from the Borg scale, and blood oxygenation should be checked before and after the test. The following variables were evaluated: heart rate, O2 saturation and Borg scale in the third minute of the test.

For the evaluation of the quality of life, the KDQOL - SF ™ 1.3 Questionnaire will be used, which is an instrument of easy administration and comprehension that has already been validated in Brazil. Its application will take place as follows: the questionnaire will be delivered to the participant and the doubts will be solved, thus enabling the individual to fill out the instrument properly. If the individual is not literate, the evaluators will only assist in reading the questionnaire and answering questions.

The level of safety will be evaluated by constant monitoring of cardiorespiratory variables, such as heart rate, oxygen pulse saturation, respiratory rate and blood pressure, which will be verified and monitored throughout the duration of the technique.

The determination of the protocol was based on a previous study carried out. After randomization of the groups the volunteers of the experimental group will carry out a proposed protocol.

Each participant will perform 30 minutes of aerobic physical activity, using cycle ergometer (Physycal, Londrina, Brazil). The exercise will begin 30 minutes after the start of hemodialysis, and will be performed three times a week for three months.

Before starting the session, a sphygmomanometer, an oximeter and a heart rate monitor will be placed during the procedure. By control, blood pressure, heart rate, peripheral saturation and the Borg Scale will be evaluated every 5 minutes. The heart rate variability will be evaluated every day between the hours of 8:00 a.m. to 12:00 a.m., in rest of 10 minutes in the positions of dorsal decubitus, sedestation and standing.

The sessions will be divided into 3 phases: heating, conditioning and cooling. In the warm-up phase 5 minutes of exercise will be performed between 60-70% of maximal heart rate, with Borg (modified) between 1 and 2. In the conditioning phase, 20 minutes of moderate exercise will be performed, with HR between 70-80% And Borg (modified) between 3 and 4. And the quench phase will be 5 min, with FC between 60-70% of the maximum and Borg (modified) between 1 and 2. The maintenance of the parameters will be regulated by the speed of realization of the exercise.

Exercise will be discontinued if the participant has a systolic pressure above 180mmHg, a diastolic pressure above 95mmHg, a 20% change in heart rate, a saturation of less than 88%, physical exhaustion, chest pain, dyspnoea, dizziness and fatigue of the exercised limbs.

02

Conditions studied

  • Chronic Kidney Diseases

Keywords

  • Chronic Kidney Disease
  • Hemodialysis
  • Exercise
03

In context

Kidney Diseases

3,840 studies on the registry are indexed under Kidney Diseases; 500 are open to participants now.

This study's enrollment of 20 is below the median of 70 across 2,640 interventional studies indexed under Kidney Diseases.

Browse Kidney Diseases studies →

Lead sponsor

Universidade Metodista de Piracicaba is the lead sponsor of 34 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Will be included in the research patients with chronic kidney disease, aged 40 to 70 years, undergoing hemodialysis

Exclusion criteria

Exclusion Criteria:

  • Will be excluded from the research, individuals who are hospitalized or that during the application of the protocol are hospitalized, have osteomioarticular diseases that prevent the proposed exercise, patients who use drugs that influence the heart rhythm , Patients with values of less than 24 points in the evaluation of the mini state of mental assessment, patients with a pacemaker installed, patients who underwent previous cardiac surgery less than six months, patients with a body mass index greater than 30 / kg / m2 .
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
20 participants (actual)

Study arms

  • Placebo comparator
    Control

    The volunteers without performing exercise during hemodialysis. Autonomic heart rate modulation, quality of life, physical fitness and safety level of exercise will be evaluated.

    Other: physical exercise

  • Experimental
    Experimental

    The volunteers will perform physical exercise during hemodialysis. Autonomic heart rate modulation, quality of life, physical fitness and safety level of exercise will be evaluated.

    Other: physical exercise

Interventions

  • Otherphysical exercise

    Each participant will perform 30 minutes of aerobic physical activity, using cycle ergometer. The exercise will begin 30 minutes after the start of hemodialysis.

06

What researchers measure

Primary outcomes

  1. Cardiac autonomic modulation by heart rate variability

    Cardiac Autonomic modulation was avaliated by Heart rate variability with Polar RS800CX

    Time frame: Change from baseline heart rate variability at 3 months

  2. Quality of life by Kidney Disease and Quality of Life Short Form 1.3 scale

    Avaliable by Kidney Disease and Quality of Life Short Form 1.3 scale, this scale was divided in 4 domains: Your Health, Kidney Disease, Effects of kidney disease on your daily life and Satisfaction with treatment, each item is put on 0 (worst) to 100 range (better)

    Time frame: Change from baseline quality of life at 3 months

  3. Functional capacity by 6-minute walk test

    avaliable by 6-minute walk test

    Time frame: Change from baseline 6-minute walk test at 3 months

07

Study locations

1 site
  • Hospital de Clínicas Gaspar Viana
    Belém, Pará 66087-660, Brazil
08

References and documents

Publications

  • Liu YM, Chung YC, Chang JS, Yeh ML. Effects of aerobic exercise during hemodialysis on physical functional performance and depression. Biol Res Nurs. 2015 Mar;17(2):214-21. doi: 10.1177/1099800414539548. Epub 2014 Jul 15. PubMed 25027035 ↗
  • National Kidney Foundation. KDOQI Clinical Practice Guideline for Hemodialysis Adequacy: 2015 update. Am J Kidney Dis. 2015 Nov;66(5):884-930. doi: 10.1053/j.ajkd.2015.07.015. Erratum In: Am J Kidney Dis. 2016 Mar;67(3):534. PubMed 26498416 ↗
  • Martin-Alemany G, Valdez-Ortiz R, Olvera-Soto G, Gomez-Guerrero I, Aguire-Esquivel G, Cantu-Quintanilla G, Lopez-Alvarenga JC, Miranda-Alatriste P, Espinosa-Cuevas A. The effects of resistance exercise and oral nutritional supplementation during hemodialysis on indicators of nutritional status and quality of life. Nephrol Dial Transplant. 2016 Oct;31(10):1712-20. doi: 10.1093/ndt/gfw297. Epub 2016 Aug 10. PubMed 27510532 ↗
  • Painter P, Carlson L, Carey S, Paul SM, Myll J. Physical functioning and health-related quality-of-life changes with exercise training in hemodialysis patients. Am J Kidney Dis. 2000 Mar;35(3):482-92. doi: 10.1016/s0272-6386(00)70202-2. PubMed 10692275 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 13, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03556540
Lead sponsor
Universidade Metodista de Piracicaba
Collaborators
Universidade do Estado do Pará
Responsible party
Rodrigo Santiago Barbosa Rocha, Phd (DOCTOR, Universidade Metodista de Piracicaba) — Principal investigator
First posted
Jun 14, 2018
Start date
Jun 1, 2017
Primary completion
Dec 1, 2018
Completion
Jan 31, 2019
Last update
Aug 13, 2020

Study contacts

Rodrigo S Rocha, Doctor
principal investigator · C

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion